We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.66%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$89.3B
AUM Growth
+$8.23B
(+10%)
Cap. Flow
+$1.9B
Cap. Flow
% of AUM
2.12%
Top 10 Holdings %
Top 10 Hldgs %
24.87%
Holding
4,460
New
1,490
Increased
1,679
Reduced
1,235
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$60.1M |
| 2 |
TSMC
TSM
|
+$59.1M |
| 3 |
Tesla
TSLA
|
+$56M |
| 4 |
Apple
AAPL
|
+$55.2M |
| 5 |
Amazon
AMZN
|
+$47.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI ACWI ex US ETF
ACWX
|
+$102M |
| 2 |
Everest Group
EG
|
+$27.4M |
| 3 |
Chevron
CVX
|
+$25M |
| 4 |
Wells Fargo
WFC
|
+$24.9M |
| 5 |
Crane NXT
CXT
|
+$13.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.27% |
| 2 | Healthcare | 12.98% |
| 3 | Financials | 12.17% |
| 4 | Consumer Discretionary | 11.18% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1676
Roivant Sciences
ROIV
$26.2B
| $3.03M | ﹤0.01% |
+300,100
| New | +$2.68M |
|
1677
Ginkgo Bioworks
DNA
$521M
| $3.02M | ﹤0.01% |
40,642
+18,023
| +80% | +$1.07M |
|
|
CCRN
1678
DELISTED
Cross Country Healthcare
CCRN
| $3.02M | ﹤0.01% |
107,674
-4,176
| -4% | -$104K |
|
|
VBTX
1679
DELISTED
Veritex Holdings
VBTX
| $3.02M | ﹤0.01% |
168,262
+1,184
| +0.7% | +$21.1K |
|
1680
PagerDuty
PD
$902M
| $3.01M | ﹤0.01% |
133,939
-5,564
| -4% | -$155K |
|
1681
Riot Platforms
RIOT
$7.76B
| $3.01M | ﹤0.01% |
254,274
-17,808
| -7% | -$199K |
|
1682
Benchmark Electronics
BHE
$2.96B
| $3M | ﹤0.01% |
116,329
-257
| -0.2% | -$5.94K |
|
1683
Magnite
MGNI
$3.55B
| $3M | ﹤0.01% |
219,887
-15,375
| -7% | -$171K |
|
|
EFC
1684
Ellington Financial
EFC
$1.71B
| $3M | ﹤0.01% |
217,194
+11,095
| +5% | +$141K |
|
1685
iShares MSCI Germany ETF
EWG
$1.62B
| $2.99M | ﹤0.01% |
+104,515
| New | +$3M |
|
1686
Helios Technologies
HLIO
$2.76B
| $2.98M | ﹤0.01% |
45,035
-262
| -0.6% | -$15.5K |
|
|
ARR
1687
Armour Residential REIT
ARR
$2.36B
| $2.97M | ﹤0.01% |
111,493
+17,355
| +18% | +$442K |
|
1688
Veracyte
VCYT
$3.8B
| $2.97M | ﹤0.01% |
116,546
-319
| -0.3% | -$7.73K |
|
1689
Preferred Bank
PFBC
$1.25B
| $2.96M | ﹤0.01% |
53,760
-570
| -1% | -$28.7K |
|
1690
Novartis
NVS
$297B
| $2.96M | ﹤0.01% |
+29,286
| New | +$2.93M |
|
|
RVNC
1691
DELISTED
Revance Therapeutics, Inc.
RVNC
| $2.94M | ﹤0.01% |
116,026
+9,415
| +9% | +$293K |
|
1692
ACV Auctions
ACVA
$1.3B
| $2.92M | ﹤0.01% |
169,330
+559
| +0.3% | +$8.55K |
|
1693
Heartland Express
HTLD
$956M
| $2.91M | ﹤0.01% |
177,288
-3,049
| -2% | -$47.5K |
|
1694
N-able
NABL
$940M
| $2.9M | ﹤0.01% |
201,214
+9,271
| +5% | +$128K |
|
|
SPNS
1695
DELISTED
Sapiens International
SPNS
| $2.9M | ﹤0.01% |
108,926
-1,641
| -1% | -$38.7K |
|
1696
iShares MSCI Qatar ETF
QAT
$64M
| $2.89M | ﹤0.01% |
+161,386
| New | +$2.98M |
|
1697
PRA Group
PRAA
$755M
| $2.89M | ﹤0.01% |
126,341
-2,163
| -2% | -$59.9K |
|
1698
Pilgrim's Pride
PPC
$6.54B
| $2.89M | ﹤0.01% |
134,281
-6,805
| -5% | -$153K |
|
1699
iShares MSCI UAE ETF
UAE
$321M
| $2.88M | ﹤0.01% |
+196,612
| New | +$2.89M |
|
|
BBT
1700
Beacon Financial Corp
BBT
$2.66B
| $2.88M | ﹤0.01% |
138,900
-8,820
| -6% | -$190K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2023 Portfolio in Review
As of Q2 2023, RhumbLine Advisers held 4,460 positions worth $89.3B, up 10% from $81B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
RhumbLine Advisers's Q2 2023 filing shows 1,490 new, 1,679 increased, 1,235 reduced and 38 closed positions. Its largest new stake was TSMC: 635,517 shares worth $64.1M. The largest sale was iShares MSCI ACWI ex US ETF, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- RhumbLine Advisers's largest Q2 2023 buy was TSMC: 635,517 shares worth $64.1M.
- RhumbLine Advisers added most to Microsoft in Q2 2023, an estimated $60.1M increase.
- RhumbLine Advisers's biggest Q2 2023 reduction was iShares MSCI ACWI ex US ETF, cutting an estimated $102M.
- RhumbLine Advisers fully exited Everest Group in Q2 2023, selling an estimated $27.4M.
- RhumbLine Advisers's ten largest holdings make up 25% of its $89.3B portfolio in Q2 2023.
- RhumbLine Advisers opened 1,490 new positions and closed 38 in Q2 2023.
- RhumbLine Advisers's portfolio value rose 10% quarter-over-quarter to $89.3B.
Based on RhumbLine Advisers's 13F filing for Q2 2023, filed 8 Aug 2023.